Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial

The FAVORIT trial is designed with sufficient power and follow-up time to detect a clinically relevant change in CVD risk between renal transplant recipients receiving a high or low tHcy-lowering folic acid multivitamin. Preliminary screening and baseline data support the trial's objectives.